Genomma's Mexican Turnaround: Winning Share in a Shrinking Market
Q2 shows a company-specific sellout inflection led by Suerox Mineral and productivity, even as the broader category and World Cup bet disappoint.
LABB.MX · Earnings Call · 2026-07-23
Mexico: The Inflection Is Company-Specific
Genomma Lab Internacional's second-quarter report is a study in contrasts. Headline net sales fell 6% (-3.6% like-for-like) and EBITDA margin compressed 200 basis points to 21.8% — yet the CEO's central message was about a turning point in Mexican demand where it matters most: sellout. Monitored Mexican sellout moved from -15.7% in April to -6.8% in June, then turned positive at +2.4% in the first two weeks of July — a 21-point recovery from Q2 2025's low point.
This is not 1 good data point. It is a consistent month by month recovery showing through our most demanding channels.
The crucial nuance: this is Genomma-specific, not a market turn. Asked whether the July uptick reflected broader category strength, management was explicit: “it is not the category... they continue to be in a negative territory.” — Juan Marco Sparvieri, Chief Executive Officer · 2026-07-23 Every category where Genomma competes in Mexico is contracting year-to-date (isotonic beverages -6.6%, OTC -6.3%, personal care -1.4%, infant nutrition -1.1%), yet the company defended market share across every business unit and even grew infant nutrition share from 4.2% to 5.2%. Its largest client, the leading retailer, is ahead of the curve — sellout rocketed from -7% in April to +15.3% in the first two weeks of July — a leading indicator management aims to replicate across other accounts.
Suerox: The Innovation Engine
The driver is Suerox Mineral, the newly launched isotonic extension. Genomma took price from 25 to 22 pesos, fully absorbed Mexico's new 1-peso-per-bottle tax on noncaloric sweetened beverages, and still expanded Suerox's Mexican gross margin by 11.7 percentage points (8pp year-over-year) — 2.8 points above pre-discount levels — while driving share at the leading retailer to a historic 12.2%. This is the productivity story in miniature. CFO Antonio Zamora Galland framed it as structural: “A clear signal that our productivity program is structural.” — Antonio Zamora Galland, Chief Financial Officer · 2026-07-23 Those productivity initiatives lifted consolidated gross margin 106bp to 64.6% with SG&A flat.
The Deliberate Trade-Off — and the Overhang
None of it is free. EBITDA fell on operational deleverage — explicitly "not by a loss of cost control." The cash conversion cycle lengthened 10 days to 129 days on a "deliberate build" of inventory for launches, and trailing-12-month free cash flow dropped 53%. Management owns the trade: “we are making the choice of reducing a little bit our guidance in terms of margin” — Juan Marco Sparvieri, Chief Executive Officer · 2026-07-23 — and expects no margin recovery before 2027, when it targets a return to the 23-24% range.
The one place company-specific momentum brushes against a shared disappointment is the World Cup. Like many consumer names (BIMBO, CCK, CMCSA, DPZ, GOOG, LVS all flagged it), Genomma loaded isotonic channels for the summer: “we loaded the channels especially in isotonic beverages. To play really hard during the World Cup” — Juan Marco Sparvieri, Chief Executive Officer · 2026-07-23 — but category demand didn't materialize, leaving "decently high" trade inventories and a possible adjustment ahead. Notably, while the global 20263 keyword slate is dominated by tariff refunds and IEEPA noise, Genomma's quarter is consumed by domestic contraction, a new soda tax, and an explicit raw-materials inflation link to the Iran situation.
LATAM and the Balance Sheet Hold the Base
While Mexico and the US recover, LATAM is compounding: Argentina grew 37.7% (4.5pp above inflation), LATAM ex-Argentina grew 5.6% with regional EBITDA margin up 41bp to 25.1%. The 10.8% appreciation of the Mexican peso is a consolidation headwind (US local-currency sales declined 21.3%), but like-for-like regional growth is real. The balance sheet stayed solid — net debt/EBITDA of 1.38x, debt service coverage of 5.2x — and a new MXN 1.5 billion, 10-year amortizing term loan extends maturities, a quiet positive that keeps the 16th consecutive quarterly dividend intact.
The underlying local-currency sellout recovery — led by Suerox and funded by productivity — is genuinely the company's own doing, in a market that is still shrinking. That is the rare kind of inflection worth watching.